This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
The Zacks Analyst Blog Highlights Roche Holding, Adobe, McDonald, Deere & Co and BP p.l.c
by Zacks Equity Research
Roche Holding, Adobe, McDonald, Deere & Co and BP p.l.c are part of Zacks top Analyst Blog.
Q2 Earnings Scorecard and Analyst Reports for Roche, Adobe & McDonald's
by Sheraz Mian
Today's Research Daily features update on the Q2 earnings season and new research reports on Roche (RHHBY), Adobe (ADBE), and McDonald's (MCD).
Prothena (PRTA) Q2 Earnings Miss, Pipeline Progress in Focus
by Zacks Equity Research
Prothena (PRTA) incurs a loss in the second quarter while revenues miss estimates.
Puma Biotech (PBYI) Stock up as Q2 Earnings & Sales Beat
by Zacks Equity Research
Puma Biotech (PBYI) beats earnings and revenue estimates in second-quarter 2022. PBYI's stock surges at market close following the news.
Amgen (AMGN) Beats Q2 Earnings Estimates, to Buy Chemocentryx
by Zacks Equity Research
Amgen (AMGN) beats Q2 estimates for earnings and sales. It offers to buy ChemoCentryx (CCXI) for $3.7 billion.
Sarepta (SRPT) Q2 Earnings Miss, DMD Drugs' Sales Robust
by Zacks Equity Research
Strong demand for Sarepta's (SRPT) DMD drugs boosts the top line in the second quarter. However, the wider-than-anticipated losses drive the stock down in after-market trading.
Regeneron (REGN) Q2 Earnings & Sales Beat on Eylea, Dupixent
by Zacks Equity Research
Regeneron (REGN) tops earnings and sales in the second quarter, driven by its lead drug Eylea and profits from asthma drug Dupixent. However, earnings decline year over year.
Blueprint Medicines' (BPMC) Q2 Earnings & Revenues Miss Mark
by Zacks Equity Research
Blueprint Medicines' (BPMC) earnings and revenues fall shy of estimates for the second quarter of 2022. However, the stock is up.
ImmunoGen (IMGN) Q2 Earnings and Revenues Miss Estimates
by Zacks Equity Research
ImmunoGen (IMGN) reports a wider-than-expected loss for second-quarter 2022. It also misses revenue estimates.
Seagen's (SGEN) Earnings & Revenues Surpass Estimates in Q2
by Zacks Equity Research
Seagen (SGEN) reports a narrower-than-expected loss in the second quarter of 2022 while its revenues beat estimates.
Roche (RHHBY) 1H22 Earnings, Sales Grow, View Disappoints
by Zacks Equity Research
Roche (RHHBY) performance in the first half was decent on demand for its diagnostics base business and new drugs. Demand for COVID-19 tests is likely to fall in the second half.
AstraZeneca (AZN) Enhertu Receives EU Nod for Expanded Use
by Zacks Equity Research
AstraZeneca (AZN) and partner Daiichi Sankyo's cancer drug, Enhertu, receives EU approval for use in adults with unresectable or metastatic HER2-positive breast cancer.
Biogen (BIIB) Beats on Q2 Earnings & Sales, Ups 2022 Guidance
by Zacks Equity Research
Biogen (BIIB) beats second-quarter estimates for both earnings and sales. Stock falls despite an increase in the 2022 outlook.
Sesen (SESN) Halts Bladder Cancer Drug Development, Stock Down
by Zacks Equity Research
Sesen Bio (SESN) decides to pause the development of Vicineum in the United States. It also ended its 2016 licensing agreement with Roche in exchange for an upfront payment of $40 million.
Novartis (NVS) Q2 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Novartis (NVS) reports mixed results in the second quarter, as key brands maintain momentum but generic competition remains a drag.
Will Biogen (BIIB) Succeed in Beating Q2 Earnings Estimates?
by Zacks Equity Research
Biogen's (BIIB) multiple sclerosis revenues have been declining since the past few quarters. It is unlikely that MS sales have improved in the second quarter.
Roche (RHHBY) Announces 2-Year Data on Vabysmo for nAMD
by Zacks Equity Research
Roche's (RHHBY) new two-year data reinforce the long-term efficacy, safety and durability of Vabysmo in wet age-related mtacular degeneration.
BAYRY vs. RHHBY: Which Stock Is the Better Value Option?
by Zacks Equity Research
BAYRY vs. RHHBY: Which Stock Is the Better Value Option?
Ionis (IONS) Partner to Begin Phase III Study on Kidney Drug
by Zacks Equity Research
Ionis (IONS) states that its partner Roche will advance IONIS-FB-L Rx into a phase III study for the treatment of IgAN after announcing positive data from a phase II study.
Pharma Stock Roundup: AZN's Small Cancer Firm Buyout, FDA Updates for PFE, RHHBY
by Kinjel Shah
FDA grants priority review to Roche's (RHHBY) BLA for Lunsumio. AstraZeneca (AZN) announces a small acquisition. Pfizer (PFE) files NDA for Paxlovid.
Roche's (RHHBY) Lunsumio Application Gets Priority Review
by Zacks Equity Research
Roche's (RHHBY) BLA application seeking approval for the use of Lunsumio for relapsed or refractory follicular lymphoma has been granted priority review in the United States.
Biogen (BIIB) Lecanemab Gets FDA Priority Tag for Alzheimer's
by Zacks Equity Research
The FDA sets a target date of Jan 6, 2023 for Biogen (BIIB) and partner Eisai's regulatory filing, which seeks accelerated approval for lecanemab to treat Alzheimer's disease (AD).
AstraZeneca (AZN) Drugs Get CHMP Recommendation for Breast Cancer
by Zacks Equity Research
The EMA's Committee for Medicinal Products for Human Use recommends granting marketing approval to AstraZeneca's (AZN) cancer drugs, Enhertu and Lynparza, for treating certain patients with breast cancer.
Sarepta (SRPT) Down on Clinical Hold on DMD Candidate SRP-5051
by Zacks Equity Research
The FDA places Sarepta's (SRPT) next-generation DMD candidate, SRP-5051, on clinical hold, following a report of hypomagnesemia in the ongoing phase II MOMENTUM study.
Exelixis (EXEL) Begins Study on XL092 Combo in Colorectal Cancer
by Zacks Equity Research
Exelixis (EXEL) starts the phase III STELLAR-303 study evaluating XL092 in combination with atezolizumab as compared to regorafenib for treating patients with metastatic colorectal cancer.